1
|
Contreras KM, Buzzi B, Vaughn J, Caillaud M, Altarifi AA, Olszewski E, Walentiny DM, Beardsley PM, Damaj MI. Characterization and validation of a spontaneous acute and protracted oxycodone withdrawal model in male and female mice. Pharmacol Biochem Behav 2024; 242:173795. [PMID: 38834159 PMCID: PMC11283946 DOI: 10.1016/j.pbb.2024.173795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Revised: 05/27/2024] [Accepted: 05/30/2024] [Indexed: 06/06/2024]
Abstract
Opioid use disorder (OUD) is a serious health problem that may lead to physical dependence, in addition to affective disorders. Preclinical models are essential for studying the neurobiology of and developing pharmacotherapies to treat these problems. Historically, chronic morphine injections have most often been used to produce opioid-dependent animals, and withdrawal signs indicative of dependence were precipitated by administering an opioid antagonist. In the present studies, we have developed and validated a model of dependence on oxycodone (a widely prescribed opioid) during spontaneous withdrawal in male and female C57BL/6J mice. Dependence was induced by chronically administering oxycodone through osmotic minipumps at different doses for 7 days. Somatic withdrawal signs were measured after 3, 6, 24, and 48 h following minipump removal. Additionally, sensitivity to mechanical, thermal, and cold stimuli, along with anxiety-like behavior, were also measured. Our results indicated that spontaneous withdrawal following discontinuation of oxycodone produced an increase in total withdrawal signs after 60 and 120 mg/kg/day regimens of oxycodone administration. These signs were reversed by the administration of clinically approved medications for OUD. In general, both female and male mice showed similar profiles of somatic signs of spontaneous withdrawal. Spontaneous withdrawal also resulted in mechanical and cold hypersensitivity lasting for 24 and 14 days, respectively, and produced anxiety-like behaviors after 2 and 3 weeks following oxycodone removal. These results help validate a new model of oxycodone dependence, including the temporally distinct emergence of somatic, hyperalgesic, and anxiety-like behaviors, potentially useful for mechanistic and translational studies of opioid dependence.
Collapse
Affiliation(s)
- Katherine M Contreras
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA
| | - Belle Buzzi
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA
| | - Julian Vaughn
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA
| | - Martial Caillaud
- Nantes Université, INSERM, UMR1235-TENS, The Enteric Nervous System in Gut and Brain Diseases, Nantes, France
| | - Ahmad A Altarifi
- Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
| | - Emily Olszewski
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA
| | - D Matthew Walentiny
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA
| | - Patrick M Beardsley
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA; Center for Biomarker Research & Precision Medicine, Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA
| | - M Imad Damaj
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA; Translational Research Initiative for Pain and Neuropathy at Virginia Commonwealth University, Richmond, VA, USA.
| |
Collapse
|
2
|
De Almeida SS, Drinkuth CR, Sartor GC. Comparing withdrawal- and anxiety-like behaviors following oral and subcutaneous oxycodone administration in C57BL/6 mice. Behav Pharmacol 2024; 35:269-279. [PMID: 38847447 PMCID: PMC11226370 DOI: 10.1097/fbp.0000000000000780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/06/2024]
Abstract
Excessive prescribing and misuse of prescription opioids, such as oxycodone, significantly contributed to the current opioid crisis. Although oxycodone is typically consumed orally by humans, parenteral routes of administration have primarily been used in preclinical models of oxycodone dependence. To address this issue, more recent studies have used oral self-administration procedures to study oxycodone seeking and withdrawal in rodents. Behavioral differences, however, following oral oxycodone intake versus parenteral oxycodone administration remain unclear. Thus, the goal of the current studies was to compare anxiety- and withdrawal-like behaviors using established opioid dependence models of either home cage oral intake of oxycodone (0.5 mg/ml) or repeated subcutaneous (s.c.) injections of oxycodone (10 mg/kg) in male and female mice. Here, mice received 10 days of oral or s.c. oxycodone administration, and following 72 h of forced abstinence, anxiety- and withdrawal-like behaviors were measured using elevated zero maze, open field, and naloxone-induced precipitated withdrawal procedures. Global withdrawal scores were increased to a similar degree following oral and s.c. oxycodone use, while both routes of oxycodone administration had minimal effects on anxiety-like behaviors. When examining individual withdrawal-like behaviors, mice receiving s.c. oxycodone exhibited more paw tremors and jumps during naloxone-induced precipitated withdrawal compared with oral oxycodone mice. These results indicate that both models of oxycodone administration are sufficient to elevate global withdrawal scores, but, when compared with oral consumption, s.c. oxycodone injections yielded more pronounced effects on some withdrawal-like behaviors.
Collapse
Affiliation(s)
| | | | - Gregory C. Sartor
- Department of Pharmaceutical Sciences, Institute for the Brain and Cognitive Sciences (IBACS), University of Connecticut, Storrs, CT 06269
| |
Collapse
|
3
|
Chen S, Liu J, Huang S. Effect of repeated intraperitoneal injections of different concentrations of oxycodone on immune function in mice. Front Pharmacol 2024; 15:1370663. [PMID: 38953110 PMCID: PMC11215192 DOI: 10.3389/fphar.2024.1370663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Accepted: 05/22/2024] [Indexed: 07/03/2024] Open
Abstract
Background The effect of oxycodone as an opioid receptor agonist on immune function is still controversial. In this study, we investigated the possible effects of oxycodone on immune function in mice and its possible mechanisms of action. Methods By repeated intraperitoneal injections of 25 mg/kg morphine and 5 mg/kg, 20 mg/kg, and 60 mg/kg oxycodone, we assessed possible changes in the number of splenic lymphocytes and inflammatory cytokines in the serum of mice. CD4+ T cells and CD8+ T cells were sorted from the spleen to observe whether the expression levels of opioid receptors and downstream signals were altered. Results Repeated administration of oxycodone at a dose above 20 mg/kg resulted in significant weight loss. Repeated administration of oxycodone exhibits significant dose-dependent reduction in CD4+ T cells, with little effect on CD8+ T cells and little effect on inflammatory cytokine levels. Low- and intermediate-dose oxycodone increased the mRNA expression level of MOR, KOR, and DOR to varying degrees. Moreover, oxycodone increases the mRNA expression levels of the TLR4 signaling pathway to varying degrees. Conclusion Repeated intraperitoneal injection of oxycodone induces immunosuppression in mice.
Collapse
Affiliation(s)
| | | | - Shaoqiang Huang
- Department of Anesthesia, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
| |
Collapse
|
4
|
Slivicki RA, Wang JG, Nhat VTT, Kravitz AV, Creed MC, Gereau RW. Impact of Δ 9-Tetrahydrocannabinol and oxycodone co-administration on measures of antinociception, dependence, circadian activity, and reward in mice. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.12.04.569809. [PMID: 38105953 PMCID: PMC10723318 DOI: 10.1101/2023.12.04.569809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2023]
Abstract
Oxycodone is commonly prescribed for moderate to severe pain disorders. While efficacious, long-term use can result in tolerance, physical dependence, and the development of opioid use disorder. Cannabis and its derivatives such as Δ9-Tetrahydrocannabinol (Δ9-THC) have been reported to enhance oxycodone analgesia in animal models and in humans. However, it remains unclear if Δ9-THC may facilitate unwanted aspects of oxycodone intake, such as tolerance, dependence, and reward at analgesic doses. This study sought to evaluate the impact of co-administration of Δ9-THC and oxycodone across behavioral measures related to antinociception, dependence, circadian activity, and reward in both male and female mice. Oxycodone and Δ9-THC produced dose-dependent antinociceptive effects in the hotplate assay that were similar between sexes. Repeated treatment (twice daily for 5 days) resulted in antinociceptive tolerance. Combination treatment of oxycodone and Δ9-THC produced a greater antinociceptive effect than either administered alone, and delayed the development of antinociceptive tolerance. Repeated treatment with oxycodone produced physical dependence and alterations in circadian activity, neither of which were exacerbated by co-treatment with Δ9-THC. Combination treatment of oxycodone and Δ9-THC produced CPP when co-administered at doses that did not produce preference when administered alone. These data indicate that Δ9-THC may facilitate oxycodone-induced antinociception without augmenting certain unwanted features of opioid intake (e.g. dependence, circadian rhythm alterations). However, our findings also indicate that Δ9-THC may facilitate rewarding properties of oxycodone at therapeutically relevant doses which warrant consideration when evaluating this combination for its potential therapeutic utility.
Collapse
Affiliation(s)
- Richard A. Slivicki
- Washington University Pain Center and Department of Anesthesiology, Washington University, St. Louis, MO
| | - Justin G. Wang
- Washington University Pain Center and Department of Anesthesiology, Washington University, St. Louis, MO
- Neuroscience Graduate Program, Division of Biology & Biomedical Sciences, Washington University, St. Louis, MO
| | - Vy Trinh Tran Nhat
- Washington University Pain Center and Department of Anesthesiology, Washington University, St. Louis, MO
| | - Alexxai V. Kravitz
- Washington University Pain Center and Department of Anesthesiology, Washington University, St. Louis, MO
- Department of Psychiatry, Washington University, St. Louis, MO
- Department of Neuroscience, Washington University, St. Louis, MO
| | - Meaghan C. Creed
- Washington University Pain Center and Department of Anesthesiology, Washington University, St. Louis, MO
- Department of Neuroscience, Washington University, St. Louis, MO
| | - Robert W. Gereau
- Washington University Pain Center and Department of Anesthesiology, Washington University, St. Louis, MO
- Department of Neuroscience, Washington University, St. Louis, MO
- Department of Biomedical Engineering, Washington University, St. Louis, MO
| |
Collapse
|
5
|
Drinkuth CR, Lehane MJ, Sartor GC. The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement. Drug Alcohol Depend 2023; 253:110987. [PMID: 37864957 PMCID: PMC10842506 DOI: 10.1016/j.drugalcdep.2023.110987] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Revised: 09/13/2023] [Accepted: 09/30/2023] [Indexed: 10/23/2023]
Abstract
Despite the thousands of lives lost during the ongoing opioid crisis, a scarcity of new and effective clinical treatments for opioid use disorder (OUD) remains. To address this unmet need, some researchers have turned to dissociative and psychedelic drugs to treat multiple psychiatric conditions. In particular, low doses of ketamine have been shown to attenuate opioid withdrawal and drug use in clinical and preclinical studies. However, ketamine has misuse liability and dissociative side effects that may limit its widespread application as a treatment for OUD. More recently, (2R,6R)-hydroxynorketamine (HNK), a ketamine metabolite that lacks misuse potential, has gained attention for its effectiveness in depression and stress models. To uncover its role in OUD, we tested the time-dependent effects of (2R,6R)-HNK on oxycodone withdrawal and reinstatement of oxycodone conditioned place preference (CPP). In male and female oxycodone-dependent mice, we found that 24h pretreatment with (2R,6R)-HNK (10 or 30mg/kg, s.c.) reduced the frequency of withdrawal-like behaviors and global withdrawal scores during naloxone-precipitated withdrawal, whereas 1h pretreatment with (2R,6R)-HNK only reduced paw tremors and the sum of global withdrawal scores but not GWS Z-scores. In other experiments, both 1h and 24h pretreatment with (2R,6R)-HNK (30mg/kg, s.c.) blocked drug-induced reinstatement of oxycodone CPP. Finally, we found (2R,6R)-HNK (30mg/kg, sc) had no effect on locomotor activity and thigmotaxis. Together, these results indicate that acute (2R,6R)-HNK has efficacy in some preclinical models of OUD without producing locomotor or anxiety-like side effects.
Collapse
Affiliation(s)
- Caryssa R Drinkuth
- Department of Pharmaceutical Sciences, Connecticut Institute for the Brain and Cognitive Sciences (IBACS), University of Connecticut, Storrs, CT 06269, United States
| | - Michael J Lehane
- Department of Pharmaceutical Sciences, Connecticut Institute for the Brain and Cognitive Sciences (IBACS), University of Connecticut, Storrs, CT 06269, United States
| | - Gregory C Sartor
- Department of Pharmaceutical Sciences, Connecticut Institute for the Brain and Cognitive Sciences (IBACS), University of Connecticut, Storrs, CT 06269, United States.
| |
Collapse
|
6
|
Wilkinson CS, Blount HL, Davis S, Rojas G, Wu L, Murphy NP, Schwendt M, Knackstedt LA. Voluntary alcohol intake alters the motivation to seek intravenous oxycodone and neuronal activation during the reinstatement of oxycodone and sucrose seeking. Sci Rep 2023; 13:19174. [PMID: 37932476 PMCID: PMC10628226 DOI: 10.1038/s41598-023-46111-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 10/26/2023] [Indexed: 11/08/2023] Open
Abstract
Opioid-alcohol polysubstance use is prevalent and worsens treatment outcomes. Here we assessed whether co-consumption of oxycodone and alcohol influence the intake of one another, demand for oxycodone, and the neurocircuitry underlying cue-primed reinstatement of oxycodone-seeking. Male and female rats underwent oxycodone intravenous self-administration (IVSA) with homecage access to alcohol (20% v/v) and/or water immediately after the IVSA session. Next, economic demand for intravenous oxycodone was assessed while access to alcohol and/or water continued. Control rats self-administered sucrose followed by access to alcohol and/or water. Rats underwent a cue-primed reinstatement test and brains were processed for c-fos mRNA expression. While both sexes decreased oxycodone intake if they had access to alcohol, and decreased alcohol intake if they had access to oxycodone, only female oxycodone + alcohol rats exhibited decreased demand elasticity and increased cue-primed reinstatement. Alcohol consumption increased the number of basolateral and central amygdala neurons activated during sucrose and oxycodone reinstatement and the number of ventral and dorsal striatum neurons engaged by sucrose reinstatement. Nucleus accumbens shell dopamine 1 receptor expressing neurons displayed activation patterns consistent with oxycodone reinstatement. Thus, alcohol alters the motivation to seek oxycodone in a sex-dependent manner and the neural circuitry engaged by cue-primed reinstatement of sucrose and oxycodone-seeking.
Collapse
Affiliation(s)
- Courtney S Wilkinson
- Psychology Department, University of Florida, 114 Psychology, 945 Center Dr., Gainesville, FL, 32611, USA
- Center for Addiction Research and Education, University of Florida, Gainesville, FL, USA
| | - Harrison L Blount
- Psychology Department, University of Florida, 114 Psychology, 945 Center Dr., Gainesville, FL, 32611, USA
- Center for Addiction Research and Education, University of Florida, Gainesville, FL, USA
| | - Shane Davis
- Psychology Department, University of Florida, 114 Psychology, 945 Center Dr., Gainesville, FL, 32611, USA
- Center for Addiction Research and Education, University of Florida, Gainesville, FL, USA
| | - Giselle Rojas
- Psychology Department, University of Florida, 114 Psychology, 945 Center Dr., Gainesville, FL, 32611, USA
| | - Lizhen Wu
- Psychology Department, University of Florida, 114 Psychology, 945 Center Dr., Gainesville, FL, 32611, USA
| | - Niall P Murphy
- Orthodontics Department, University of Florida, Gainesville, FL, USA
| | - Marek Schwendt
- Psychology Department, University of Florida, 114 Psychology, 945 Center Dr., Gainesville, FL, 32611, USA
- Center for Addiction Research and Education, University of Florida, Gainesville, FL, USA
| | - Lori A Knackstedt
- Psychology Department, University of Florida, 114 Psychology, 945 Center Dr., Gainesville, FL, 32611, USA.
- Center for Addiction Research and Education, University of Florida, Gainesville, FL, USA.
| |
Collapse
|
7
|
Barrett JE, Shekarabi A, Inan S. Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments. Pharmacol Rev 2023; 75:1062-1118. [PMID: 37321860 PMCID: PMC10595024 DOI: 10.1124/pharmrev.121.000506] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 04/30/2023] [Accepted: 06/05/2023] [Indexed: 06/17/2023] Open
Abstract
Oxycodone, a semisynthetic derivative of naturally occurring thebaine, an opioid alkaloid, has been available for more than 100 years. Although thebaine cannot be used therapeutically due to the occurrence of convulsions at higher doses, it has been converted to a number of other widely used compounds that include naloxone, naltrexone, buprenorphine, and oxycodone. Despite the early identification of oxycodone, it was not until the 1990s that clinical studies began to explore its analgesic efficacy. These studies were followed by the pursuit of several preclinical studies to examine the analgesic effects and abuse liability of oxycodone in laboratory animals and the subjective effects in human volunteers. For a number of years oxycodone was at the forefront of the opioid crisis, playing a significant role in contributing to opioid misuse and abuse, with suggestions that it led to transitioning to other opioids. Several concerns were expressed as early as the 1940s that oxycodone had significant abuse potential similar to heroin and morphine. Both animal and human abuse liability studies have confirmed, and in some cases amplified, these early warnings. Despite sharing a similar structure with morphine and pharmacological actions also mediated by the μ-opioid receptor, there are several differences in the pharmacology and neurobiology of oxycodone. The data that have emerged from the many efforts to analyze the pharmacological and molecular mechanism of oxycodone have generated considerable insight into its many actions, reviewed here, which, in turn, have provided new information on opioid receptor pharmacology. SIGNIFICANCE STATEMENT: Oxycodone, a μ-opioid receptor agonist, was synthesized in 1916 and introduced into clinical use in Germany in 1917. It has been studied extensively as a therapeutic analgesic for acute and chronic neuropathic pain as an alternative to morphine. Oxycodone emerged as a drug with widespread abuse. This article brings together an integrated, detailed review of the pharmacology of oxycodone, preclinical and clinical studies of pain and abuse, and recent advances to identify potential opioid analgesics without abuse liability.
Collapse
Affiliation(s)
- James E Barrett
- Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University. Philadelphia, Pennsylvania
| | - Aryan Shekarabi
- Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University. Philadelphia, Pennsylvania
| | - Saadet Inan
- Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University. Philadelphia, Pennsylvania
| |
Collapse
|
8
|
Wilkinson CS, Blount HL, Davis S, Rojas G, Wu L, Murphy NP, Schwendt M, Knackstedt LA. Voluntary alcohol intake alters the motivation to seek intravenous oxycodone and neuronal activation during the reinstatement of oxycodone and sucrose seeking. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.07.20.549769. [PMID: 37546763 PMCID: PMC10401968 DOI: 10.1101/2023.07.20.549769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/08/2023]
Abstract
Opioid-alcohol polysubstance use is prevalent and worsens treatment outcomes. Here we assessed whether co-consumption of oxycodone and alcohol would influence intake of one another, demand for oxycodone, and the neurocircuitry underlying cue-primed reinstatement of oxycodone-seeking. Male and female rats underwent oxycodone intravenous self-administration (IVSA) with access to either alcohol (20% v/v) and water or only water immediately after the IVSA session. Next, economic demand for intravenous oxycodone was assessed while access to alcohol and/or water continued. Control rats self-administered sucrose followed by access to alcohol and/or water. Rats underwent extinction training and brains were processed for c-fos mRNA expression immediately following a cue-primed reinstatement test. While both sexes decreased oxycodone intake if they had access to alcohol, and decreased alcohol intake if they had access to oxycodone, female oxycodone+alcohol rats exhibited decreased demand elasticity for intravenous oxycodone and increased cue-primed reinstatement while male rats did not. Spontaneous withdrawal signs were correlated with oxycodone intake while alcohol intake was correlated with anxiety-like behavior. Alcohol consumption increased the number of basolateral and central amygdala neurons activated during sucrose and oxycodone reinstatement and the number of ventral and dorsal striatum neurons engaged by sucrose reinstatement. Nucleus accumbens shell dopamine 1 receptor containing neurons displayed activation patterns consistent with oxycodone reinstatement. Thus, alcohol alters the motivation to seek oxycodone in a sex-dependent manner and alters the neural circuitry engaged by cue-primed reinstatement of sucrose and oxycodone-seeking.
Collapse
Affiliation(s)
- Courtney S. Wilkinson
- Psychology Dept. University of Florida, Gainesville, FL
- Center for Addiction Research and Education, University of Florida, Gainesville, FL
| | - Harrison L. Blount
- Psychology Dept. University of Florida, Gainesville, FL
- Center for Addiction Research and Education, University of Florida, Gainesville, FL
| | - Shane Davis
- Psychology Dept. University of Florida, Gainesville, FL
- Center for Addiction Research and Education, University of Florida, Gainesville, FL
| | - Giselle Rojas
- Psychology Dept. University of Florida, Gainesville, FL
| | - Lizhen Wu
- Psychology Dept. University of Florida, Gainesville, FL
| | | | - Marek Schwendt
- Psychology Dept. University of Florida, Gainesville, FL
- Center for Addiction Research and Education, University of Florida, Gainesville, FL
| | - Lori A. Knackstedt
- Psychology Dept. University of Florida, Gainesville, FL
- Center for Addiction Research and Education, University of Florida, Gainesville, FL
| |
Collapse
|
9
|
El Jordi O, Fischer KD, Meyer TB, Atwood BK, Oblak AL, Pan RW, McKinzie DL. Microglial knockdown does not affect acute withdrawal but delays analgesic tolerance from oxycodone in male and female C57BL/6J mice. ADVANCES IN DRUG AND ALCOHOL RESEARCH 2022; 2:10848. [PMID: 38390615 PMCID: PMC10880796 DOI: 10.3389/adar.2022.10848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 12/05/2022] [Indexed: 02/24/2024]
Abstract
Opioid Use Disorder (OUD) affects approximately 8%-12% of the population. In dependent individuals, abrupt cessation of opioid taking results in adverse withdrawal symptoms that reinforce drug taking behavior. Considerable unmet clinical need exists for new pharmacotherapies to treat opioid withdrawal as well as improve long-term abstinence. The neuroimmune system has received much scientific attention in recent years as a potential therapeutic target to combat various neurodegenerative and psychiatric disorders including addiction. However, the specific contribution of microglia has not been investigated in oxycodone dependence. Chronic daily treatment with the CSF1R inhibitor Pexidartinib (PLX3397) was administered to knockdown microglia expression and evaluate consequences on analgesia and on naloxone induced withdrawal from oxycodone. In vivo results indicated that an approximately 40% reduction in brain IBA1 staining was achieved in the PLX treatment group, which was associated with a delay in the development of analgesic tolerance to oxycodone and maintained antinociceptive efficacy. Acute withdrawal behavioral symptoms, brain astrocyte expression, and levels of many neuroinflammatory markers were not affected by PLX treatment. KC/GRO (also known as CXCL1) was significantly enhanced in the somatosensory cortex in oxycodone-treated mice receiving PLX. Microglial knock-down did not affect the expression of naloxoneinduced opioid withdrawal but affected antinociceptive responsivity. The consequences of increased KC/GRO expression within the somatosensory cortex due to microglial reduction during opioid dependence are unclear but may be important for neural pathways mediating opioid-induced analgesia.
Collapse
Affiliation(s)
- Omar El Jordi
- Department of Pharmacology and Toxicology, Indiana University, Indianapolis, IN, United States
| | - Kathryn D Fischer
- Department of Pharmacology and Toxicology, Indiana University, Indianapolis, IN, United States
| | - Timothy B Meyer
- Department of Pharmacology and Toxicology, Indiana University, Indianapolis, IN, United States
| | - Brady K Atwood
- Department of Pharmacology and Toxicology, Indiana University, Indianapolis, IN, United States
| | - Adrian L Oblak
- Department of Radiology and Imaging Sciences, Indiana University, Indianapolis, IN, United States
| | - Raymond W Pan
- Department of Pharmacology and Toxicology, Indiana University, Indianapolis, IN, United States
| | - David L McKinzie
- Department of Pharmacology and Toxicology, Indiana University, Indianapolis, IN, United States
| |
Collapse
|
10
|
Dodu JC, Moncayo RK, Damaj MI, Schlosburg JE, Akbarali HI, O'Brien LD, Kendall DA, Wu Z, Lu D, Lichtman AH. The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice. J Pharmacol Exp Ther 2022; 380:1-14. [PMID: 34625464 PMCID: PMC8969135 DOI: 10.1124/jpet.121.000723] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 10/01/2021] [Indexed: 01/03/2023] Open
Abstract
Opioid use disorder reflects a major public health crisis of morbidity and mortality in which opioid withdrawal often contributes to continued use. However, current medications that treat opioid withdrawal symptoms are limited by their abuse liability or lack of efficacy. Although cannabinoid 1 (CB1) receptor agonists, including Δ9-tetrahydrocannabinol, ameliorate opioid withdrawal in both clinical and preclinical studies of opioid dependence, this strategy elicits cannabimimetic side effects as well as tolerance and dependence after repeated administration. Alternatively, CB1 receptor positive allosteric modulators (PAMs) enhance CB1 receptor signaling and show efficacy in rodent models of pain and cannabinoid dependence but lack cannabimimetic side effects. We hypothesize that the CB1 receptor PAM ZCZ011 attenuates naloxone-precipitated withdrawal signs in opioid-dependent mice. Accordingly, male and female mice given an escalating dosing regimen of oxycodone, a widely prescribed opioid, and challenged with naloxone displayed withdrawal signs that included diarrhea, weight loss, jumping, paw flutters, and head shakes. ZCZ011 fully attenuated naloxone-precipitated withdrawal-induced diarrhea and weight loss and reduced paw flutters by approximately half, but its effects on head shakes were unreliable, and it did not affect jumping behavior. The antidiarrheal and anti-weight loss effects of ZCZ0111 were reversed by a CB1 not a cannabinoid receptor type 2 receptor antagonist and were absent in CB1 (-/-) mice, suggesting a necessary role of CB1 receptors. Collectively, these results indicate that ZCZ011 completely blocked naloxone-precipitated diarrhea and weight loss in oxycodone-dependent mice and suggest that CB1 receptor PAMs may offer a novel strategy to treat opioid dependence. SIGNIFICANCE STATEMENT: Opioid use disorder represents a serious public health crisis in which current medications used to treat withdrawal symptoms are limited by abuse liability and side effects. The CB1 receptor positive allosteric modulator (PAM) ZCZ011, which lacks overt cannabimimetic behavioral effects, ameliorated naloxone-precipitated withdrawal signs through a CB1 receptor mechanism of action in a mouse model of oxycodone dependence. These results suggest that CB1 receptor PAMs may represent a viable strategy to treat opioid withdrawal.
Collapse
Affiliation(s)
- Julien C Dodu
- Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.)
| | - Rebecca K Moncayo
- Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.)
| | - M Imad Damaj
- Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.)
| | - Joel E Schlosburg
- Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.)
| | - Hamid I Akbarali
- Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.)
| | - Lesley D O'Brien
- Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.)
| | - Debra A Kendall
- Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.)
| | - Zhixing Wu
- Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.)
| | - Dai Lu
- Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.)
| | - Aron H Lichtman
- Department of Pharmacology & Toxicology (J.C.D., R.K.M., M.I.D., J.E.S., H.I.A., L.D.O., A.H.L.), and Department of Medicinal Chemistry (A.H.L.), Virginia Commonwealth University, Richmond, Virginia; Department of Pharmaceutical Sciences, University of Connecticut, Mansfield, Connecticut (D.A.K.); and Department of Pharmaceutical Sciences, Texas A&M, College Station, Texas (Z.W., D.L.)
| |
Collapse
|